Mevrometostat plus enzalutamide in metastatic castration-resistant

Trial
100%75%50%25%0%Jun 24Jun 25Jun 24 00:18 UTC • YES 44.0%Jun 24 00:18 UTC • YES 44.0%Jun 24 00:20 UTC • YES 44.0%Jun 24 00:20 UTC • YES 44.0%Jun 24 00:20 UTC • YES 44.0%Jun 24 00:20 UTC • YES 44.0%Jun 24 15:21 UTC • YES 44.0%Jun 24 15:21 UTC • YES 44.0%Jun 24 15:23 UTC • YES 44.0%Jun 24 15:23 UTC • YES 44.0%Jun 24 15:23 UTC • YES 44.0%Jun 24 15:23 UTC • YES 44.0%Jun 24 18:31 UTC • YES 44.0%Jun 24 19:10 UTC • YES 50.0%Jun 24 19:16 UTC • YES 55.3%Jun 24 19:16 UTC • YES 60.0%Jun 24 22:32 UTC • YES 64.1%Jun 24 22:34 UTC • YES 62.9%Jun 24 22:35 UTC • YES 61.9%Jun 24 22:35 UTC • YES 60.8%Jun 24 22:36 UTC • YES 59.8%Jun 24 22:37 UTC • YES 58.7%Jun 24 22:38 UTC • YES 57.6%Jun 24 22:39 UTC • YES 56.5%Jun 24 22:40 UTC • YES 55.4%Jun 25 12:00 UTC • YES 55.3%Jun 25 15:55 UTC • YES 55.3%Jun 25 15:56 UTC • YES 55.3%Jun 25 16:02 UTC • YES 55.3%
ResolvedYES
Oracle Evidence
Resolved Date
12/2/26
Study Completion
11/30/28
Sponsor
Pfizer
Ticker
$PFE
Type
Phase 3
Trial Status
RECRUITING
Trial Size
900
NCT
NCT06629779
Trial Description
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide works better than enzalutamide alone in participants with metastatic castration-resistant prostate cancer who are ARSi or abiraterone naive.